新闻

Featured press release

Certara 凭借超过 100 篇发表的论文，展示 2024 年研究成果的辉煌成就

The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list RADNOR, PA – 2024 年 12 月 2 日 – Certara, Inc.…

Latest press releases

All Press Release

Press Release

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Press Release

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Press Release

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Category Heading

All Announcement

Announcement

Certara Announces Second Annual Certainty U.S. Event

Announcement

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

Announcement

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Announcement

Certara 获欧洲药品管理局项目授权，评估 CAR-T 细胞疗法的真实世界数据环境

Announcement

Certara 任命生物统计、数据科学与准入部门新负责人

Announcement

Certara 推出更新版 SEND Explorer® 软件

All resources heading

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

建模和模拟, 新闻发布

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

新闻发布

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Certara Products - Simcyp, Press Release

Be the first to get the latest

Transforming drug development is not just our goal—it’s our obsession. 如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

新闻

Featured press release

Certara 凭借超过 100 篇发表的论文，展示 2024 年研究成果的辉煌成就

Latest press releases

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Category Heading

Certara Announces Second Annual Certainty U.S. Event

Certara & A2Healthcare accelerate Model-informed Drug Development (MIDD) adoption in Japan

Certara Enters Strategic Partnership with Biowaived to Increase Biopharmaceutics Capabilities

Certara 获欧洲药品管理局项目授权，评估 CAR-T 细胞疗法的真实世界数据环境

Certara 任命生物统计、数据科学与准入部门新负责人

Certara 推出更新版 SEND Explorer® 软件

All resources heading

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

Certara Reports Preliminary First Quarter 2025 Financial Results Announces $100 Million Share Repurchase Authorization

Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities

Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Certara 公布 2024 年第四季度财报

Certara 将于 2025 年 2 月 26 日公布 2024 年第四季度和全年财报，并参加即将举行的投资者会议

Certara 公布 2024 年第四季度和全年初步财务报告

Certara 将参加第 43 届摩根大通（J.P. Morgan）医疗保健年会

Certara 凭借超过 100 篇发表的论文，展示 2024 年研究成果的辉煌成就

Certara 第三季度报告2024财务业绩

Certara to Participate in the Stephens Annual Investment Conference

Certara 任命 John Reynders 为新的独立董事会成员

订阅时事通讯

快捷链接

解决方案

联系我们